# A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients

> **NCT00739648** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 322 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** MP-376
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00739648
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2010-01
- **Final completion:** 2010-04
- **Target enrollment:** 322 (ACTUAL)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00739648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00739648, "A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00739648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*